Pharvaris N.V. (PHVS)
NASDAQ: PHVS · Real-Time Price · USD
17.16
+0.16 (0.94%)
At close: Jun 30, 2025, 4:00 PM
17.60
+0.44 (2.56%)
After-hours: Jun 30, 2025, 4:00 PM EDT
Pharvaris Employees
Pharvaris had 108 employees as of December 31, 2024. The number of employees increased by 26 or 31.71% compared to the previous year.
Employees
108
Change (1Y)
26
Growth (1Y)
31.71%
Revenue / Employee
n/a
Profits / Employee
-$1,526,633
Market Cap
935.10M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
PHVS News
- 3 days ago - Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit - GlobeNewsWire
- 14 days ago - Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress - GlobeNewsWire
- 20 days ago - Pharvaris Announces Annual Meeting of Shareholders - GlobeNewsWire
- 4 weeks ago - Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema - GlobeNewsWire
- 6 weeks ago - Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses - GlobeNewsWire
- 6 weeks ago - Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4 - GlobeNewsWire
- 3 months ago - Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire